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This study aimed to examine resumption of Attention Deficit Hyperactivity Disorder (ADHD) 
prescriptions in early adulthood in young people whose ADHD prescriptions stopped in adolescence. 
Whilst prescribing studies indicate that the proportion of those with ADHD stopping treatment in late 
adolescence remains in excess of the proportion expected to be symptom free, very few studies have 
examined patterns of resumption amongst young adults previously prescribed medication. 
Primary care records from the UK Clinical Practice Research Datalink from 2008 to 2013 were used 
to examine the outcome of resumption of ADHD prescriptions from age 20 years in a sample of cases 
with ADHD whose prescriptions stopped aged 14-18.  A Cox regression model was fitted to explore 
variables that could theoretically be associated with resumption of prescriptions. 
Of 1,440 cases, 109 (7.6%) had their ADHD prescriptions resumed. Characteristics associated with an 
increased probability of resumption included female gender, learning disability, referral to adult 
mental health services, and prescription of antipsychotic medication. 
In this study, only a small proportion of adolescents who stopped ADHD medication subsequently 
resumed their prescriptions in primary care. Those that did resume were a more complex group.  As 
many vulnerable individuals with ongoing ADHD symptoms may not have the resources required to 
surmount the barriers to re-enter services, the implication is that not all those who could benefit from 
resuming medication are able to do so. The findings raise questions around whether current care 
models are flexible enough and whether primary care are adequately supported in managing this 
group. 
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Attention Deficit Hyperactivity Disorder (ADHD) is now accepted to be a condition which can persist 
throughout life. Follow-up studies suggest that up to three-quarters of young people diagnosed as 
children continue to experience symptoms into adulthood, even if they no longer meet full diagnostic 
criteria (1). These symptoms, which include inattention, impulsivity, and hyperactivity, can 
undermine the fulfilment of adult responsibilities such as further education, employment, intimate 
relationships and parenting, and are associated with risk-taking behaviours, accidents and injuries (2-
5).  
Consequently, much recent research has focussed on ADHD management during the transition to 
adulthood, and in particular on the prescription of ADHD medication. In studies from the UK, US and 
Europe (6-9), the proportion of young people stopping medication during this period appears to be in 
excess of the proportion expected to be symptom free from follow-up studies (1). For those with 
ongoing symptoms, cessation of medication is likely to represent a complex combination of choice 
and circumstance. During adolescence, young people are expected to become involved in decision 
making about their treatment, and may experiment with starting and stopping medication, and with 
alternative coping strategies (10-12). Medication is also often perceived as an intervention intended to 
allow the young person to cope with school and once exams are finished, the adverse effects may be 
seen to outweigh the benefits (12-14). External factors may influence ongoing prescribing, such as a 
lack of services or expertise to oversee medication management in adults, or a lack of support, 
resource and preparation for transition to adult services that leads both services and young people to 
disengage even before the age boundary for the service is reached (14-16).   
Stopping medication can have positive outcomes for many young people, but for others, cessation 
may be detrimental and destabilising at a vulnerable life stage. Arguably, we would therefore expect 
to see a prescribing pattern whereby some adolescents with continuing symptoms stop medication but 
later seek to re-start treatment as young adults. Guidance from the UK National Institute for Health 
and Care Excellence (NICE) now recognises that people with ADHD previously treated as children 
may return to services after the age of 18 seeking support and treatment for continuing ADHD 
symptoms (17).  
This group of young adults who do not undergo transition into an adult service for their ADHD but 
then seek to re-enter services and potentially resume treatment have been little studied to date. 
Therefore, there is a gap in knowledge about the scale and needs of this group, which is important for 
planning services and training.   Very few studies have examined patterns of resumption amongst 
young people previously prescribed medication. Notably, whilst the USA-based large Multimodal 
Treatment of Attention Deficit Hyperactivity Disorder (MTA) trial reported on ‘stopping and 
restarting’ patterns in adolescents, it has not published data on resumption after the age of 18 (12). In 
the UK, Wong et al. described resumption in the General Practice Research Datalink from 1999 to 
2006 amongst patients who had stopped after the age of 15 (18).  Only 56 of the 407 individuals who 
stopped restarted treatment during the follow-up period, the majority in the first year after cessation; 
however, this study took place prior to the publication of the first UK NICE ADHD guidance that 
referred to adults in 2008 (19). 
We aimed to explore resumption of ADHD medication prescriptions in early adulthood (from age 20 
onwards) amongst young people whose prescriptions stopped in adolescence (aged 14-18) using 
primary care prescribing data from the UK Clinical Practice Research Datalink from 2008 to 2013. 
The age range of 14-18 years for cessation was chosen as it corresponds to adolescence and the period 
of preparation for transition to adult healthcare services; this is the time at which young people are 
most likely to cease their ADHD medication (8, 9). We studied resumption from the age of 20 
onwards, in order to capture prescribing in adult services rather than extended prescribing in child 
services. 
Our chief research questions were 
 What proportion of young people who have previously been prescribed ADHD medication 
and stopped resume prescriptions in early adulthood, and what is the probability of resuming 
medication from age 20 years onwards? 




This study was a secondary analysis of data from the Clinical Practice Research Datalink (CPRD), a 
large UK clinical database run by the Medicines and Healthcare products Regulatory Agency 
(MHRA). The primary care section of the database contains the records of over 11 million patients 
and is contributed to by more than 670 GP practices across the UK, covering over 6% of the 
population (20). CPRD uses software to extract anonymised data from participating practices’ IT 
systems. Records of each patient are coded by GPs and practice staff according to NHS coding 
schemes, and all primary-care issued prescriptions are automatically captured. All protocols using 
patient-level data from the CPRD are reviewed and approved by the Independent Scientific Advisory 
Committee on behalf of the National Research Ethics Service Committee. This study protocol 
(13_213) was granted approval in 2013. 
Patients 
The sample for this analysis used a subset of a larger dataset of patients (N=9390) with a recorded 
diagnosis of ADHD using NHS coding schemes (described in Newlove-Delgado et al. (9)). Recorded 
psychiatric diagnoses were identified using CPRD medical codes and READ term codes used in UK 
primary care, which map to ICD-10 categories (21). Psychotropic prescribing (including for ADHD 
medication) was categorised using CPRD product codes referring to British National Formulary 
categories (22).   The dataset included patients aged between 10 and 20 in 2005, and the study period 
ran from 1st Jan 2005 until 31st Dec 2013. 
In order to be included in this analysis, patients had to: 
 Have at least one year’s worth of prescribing records for an ADHD medication, to ensure this 
was a regular prescription and not a ‘trial’ of medication 
 Have their last recorded prescription for an ADHD medication issued between the ages of 14 
and 18 (inclusive); with no further ADHD prescribing recorded until the age of 20 if at all 
 Have at least one year’s worth of follow-up data in the CPRD from the age of 20 
Analysis 
Resumption was defined as having at least one recorded prescription of ADHD medication at the age 
of 20 or over.  We reported the percentage of included cases who resumed prescriptions and the age of 
re-starting, and the percentage of those who resumed prescriptions by age at stopping. The percentage 
of those who resumed medication was then reported by key characteristics (gender, non-ADHD 
prescription status, recorded referral to Adult Mental Health Services and non-ADHD psychiatric 
diagnoses).  We also reported the prescription of non-ADHD psychotropic medication in individuals 
who did and did not resume ADHD prescriptions, and used the Chi-squared test to compare 
proportions. 
We then performed survival analysis to examine the time to resumption of ADHD prescriptions. The 
observation period for the survival analysis began from the year of the case’s 20th birthday and 
continued until a new prescription for an ADHD medication was recorded (resumption), until records 
for the patient were no longer available or the study period ended (31st December 2013) – i.e. they 
were censored. The median time to resumption was reported and the distribution of time to 
resumption was summarised using the Kaplan-Meier estimator.  A Cox regression model was fitted to 
explore variables that could theoretically be associated with resumption of prescription, based on the 
previous descriptive analysis. These included gender, referral to adult psychiatry, non-ADHD 
psychotropic primary care prescribing aged 18 and under or aged 19 and over, and recorded 
psychiatric comorbidities, as well as age at stopping medication. Each variable was initially examined 
in an unadjusted Cox regression model, reporting hazard ratios. Predictor variables with a p-value less 
than 0.05 were then included in a multivariable (adjusted) Cox regression model, with the same tests 
of the proportional hazards assumption applied. The proportional hazards assumption was checked by 
examining Schoenfeld residuals and plotting Nelson–Aalen cumulative hazard estimates. Statistical 
analyses were carried out using Stata software (version 14) (23). 
Findings 
There were 1,440 young people in the analysis who met our inclusion criteria. Of these, 1,293 were 
male (89.8%), 395 (27.4%) had a prescription for a non-ADHD psychotropic medication at any point, 
348 (24.2%) had a recorded diagnosis of another psychiatric disorder (excluding learning disability), 
and 64 (4.4%) had a recorded learning disability. 
In our sample, 109 participants (7.6%, 95% CI 6.3 to 9.1%) had their prescriptions resumed at the age 
of 20 or over. Of the 147 females in the sample, 17 (11.6%) resumed medication, compared to 92 of 
1,293 males (7.1%).  
Ages of stopping and resuming medication 
Of the 1,440 participants, 427 (29.7%) stopped medication at age 16, which was the most common 
age for cessation, although 372 participants (25.8%) stopped medication at 17 and 319 (22.2%) at 18.  
Table 1 displays the percentage of young people in our sample whose prescriptions were resumed at 
specific ages. The majority of those who did re-start did so before the age of 22 years. 
Insert Table 1 here 
Once prescriptions were resumed, the median duration of persistence was one year (interquartile 
range one year to four years) with the range from less than a year to five years; cases still prescribed 
medication at six years or more post resumption were censored (see Methods section). 
Overall, the later the young person stopped medication, the more likely they were to restart 
prescriptions in early adulthood. Only 6 (5.3%) of the 113 who stopped medication at age 14 resumed 
medication, compared to 42 (13.2%) of the 319 who stopped medication aged 18 (Table 2). 
Insert Table 2 here 
Resumption of primary care prescriptions for ADHD medication by characteristic 
Table 3 describes the number and percentage of young people with different characteristics, whose 
ADHD prescriptions resumed in early adulthood.  Resumption levels were highest amongst cases with 
a recorded referral to adult mental health services, those with a learning disability, and those 
prescribed a non-ADHD psychotropic medication (Table 3). In terms of psychiatric diagnoses, of the 
35 cases in the sample with a substance misuse diagnosis, six resumed medication for their ADHD, 
compared to nine of the 92 with conduct or oppositional defiant disorder. 
Insert Table 3 here 
Time to resumption 
The cumulative percentage of prescription resumption rose with age but then remained stable from the 
age of 24; additionally far fewer cases remained in the survival analysis after this point with a high 
proportion being censored. The estimated cumulative probability of resumption at one year (by age 
20) was 4.6% (95% CI 3.5% to 5.8%); at three years (by the age of 22) this had risen to 7.6% (95% CI 
6.3% to 9.2%) and at five years (by age 24) this was 9.7% (95% CI 7.7% to 12.0%). 
Factors associated with resumption 
The probability of resumption rose most steeply in the first two years of observation from age 20. 
When fitting the Cox regression model, there was evidence of violation of the proportional hazards 
assumption for some variables when examining resumption over the full follow-up period (see 
Methods). Table 4 therefore presents the Cox regression model for the three year period when cases 
were aged 20-22, where the proportional hazards assumption was met. 
Insert Table 4 here 
In the adjusted model, female gender remained associated with an increased probability of 
resumption, as did a recorded referral to adult mental health services and having a recorded learning 
disability diagnosis. Prescription of antipsychotic medication was also strongly associated with 
resumption. Those that were older at the time of stopping medication also appeared to be more likely 
to re-start within this time period. 
Comparison of Non-ADHD psychotropic prescribing in individuals who did and did not resume 
ADHD prescriptions 
As shown in Table 5, prescribing of all categories of non-ADHD psychotropic medication was more 
common in young people resuming prescriptions. Almost half of those who resumed ADHD 
prescriptions also had a primary care prescription for a non-ADHD psychotropic medication. 
Prescription of different categories of non-ADHD psychotropics (e.g. an antidepressant and an 
antipsychotic) was also more common in those with prescription resumption. 




International studies have demonstrated that the majority of young people with ADHD stop 
medication by the age of 18 (6-9). Our findings indicate that only a small proportion subsequently 
resume their prescriptions in primary care.  In our study, the younger the age at stopping medication, 
the less likely individuals were to resume in early adulthood.  We found that those resuming 
prescriptions on average were diagnosed with more comorbid psychiatric conditions and were more 
likely to be prescribed multiple psychotropic medications, making their management more complex 
and reinforcing the importance of specialist psychiatric oversight (24). 
Discussion and comparison with existing literature 
The low prevalence of resumption in our study is in line with earlier work by Wong et al. which 
examined prescribing between 1999 and 2006 (18). Our more recent finding still demands discussion 
of the current context in which prescribing is taking place in order to consider the implications. 
We found that the younger the age at stopping, the less likely cases were to resume their prescriptions. 
Continuing to take medication into late adolescence is logically likely to be a marker of severity of 
symptoms; although notably the age of stopping prescriptions was associated with resumption in our 
Cox regression even after adjusting for psychiatric co-morbidities (often related to severity).  It is 
possible that the young people stopping medication earlier in adolescence are those who experienced 
remission of their ADHD, and who consequently underwent a planned cessation of medication. 
Correspondingly, those who stopped later around the age of leaving child services may have 
encountered the ‘twilight zone’ of transition described by Young et al. (25), and the structural barriers 
to ongoing support and prescribing, including a lack of transition planning and protocols, and the well 
documented lack of services for adults with ADHD (15,16, 26). The ‘late stoppers’ could therefore 
represent a group more likely to have experienced a more sudden and unplanned cessation of their 
ADHD medication, and who might therefore seek to resume at a later point. Stopping early may be 
more likely among those who struggle to tolerate drug treatment or who derive little benefit - although 
the inclusion criteria for this study required cases to have a year or more of prescriptions, this does not 
equate to adherence to taking medication. Both processes are likely to have been in operation in the 
current study. 
We found that female gender was also associated with an increased probability of resumption.  It is 
feasible that gender differences in help-seeking behaviour exist which could influence re-engagement 
with services (27); however, it has also been suggested that young women prescribed medication may 
be more impaired as they face higher barriers to diagnosis and treatment in the first place (28). 
Overall, a higher proportion of those restarting medication had a psychiatric comorbidity recorded at 
some point, with the most common being anxiety and depression, but none of the comorbid conditions 
were significant predictors of resumption in our adjusted Cox model. It is worth noting that comorbid 
conditions recorded in primary care may also be mislabelled; Asherson et al. have argued that lack of 
recognition of the clinical presentation of ADHD in adulthood may lead to under-treatment, or to 
substitution of other psychotropic medication for ADHD medication if the symptoms are mistaken for 
the signs of other common psychiatric disorders (29).  
A study of adults with a new diagnosis of ADHD in the CPRD noted high rates of primary care 
prescribing of non-ADHD psychotropic medication in this group, with 16% being prescribed 
antipsychotic medication (30). In our analysis, those resuming prescription of ADHD medication 
were also more likely to be prescribed all types of psychotropic medication, which could represent an 
indicator of contact with specialist mental health services, particularly for those prescribed 
antipsychotics. We found that only a quarter of those resuming prescriptions actually had an adult 
mental health services referral coded in CPRD, suggesting that referrals may be under-recorded, 
and/or that some resumption may not be taking place under specialist supervision, possibly linked to a 
lack of appropriate services. This finding is similar to that reported by Bushe et al., who found that 
only a third of adults with an incident ADHD diagnosis had a secondary care referral recorded in 
CPRD (30).  
Strengths and limitations 
This is the only study we are aware of to explore resumption of ADHD prescribing in early adulthood 
in UK primary care since the introduction of the 2008 NICE Guidance (19). It uses the CPRD 
database which is broadly representative of the UK population, and is likely to provide the fullest 
picture of prescribing due to widespread shared-care protocols for ADHD (20, 31). Having said this, 
we acknowledge that our study is likely to represent an underestimate of resumption to some extent, 
for example in cases where ADHD medication is resumed and prescribed solely in specialist services, 
or by private psychiatrists.   
The low proportion of cases with a recorded secondary care referral also suggests that referrals were 
under-recorded or perhaps recorded as free text (which is unavailable to researchers, for fear of de-
anonymisation); this consideration does limit any conclusions we can draw about the level of 
oversight and specialist support for resumption (30).  
This study examines only medication prescribing. There is no way of knowing whether or not the 
cases included in this study were actually taking their medication as prescribed, and whether they 
stopped medication when prescribing ceased or at a much earlier point. Non-adherence is estimated to 
be widespread in ADHD, and is also influenced by factors such as socio-economic status, beliefs and 
attitudes and of course adverse effects and medication effectiveness, which we were unable to take 
into account when considering differences between those who did and did not resume their 
prescriptions (32,33). 
Unfortunately, our exploration of resumption in this respect was also limited by the absence of data on 
symptoms and severity of ADHD recorded in CPRD. Even so, we were able to examine age at 
stopping, recorded psychiatric comorbidities and non-ADHD psychotropic prescribing, all of which 
provide information characterising who did and did not resume prescriptions and can direct future 
research. 
Clinical implications  
The low prevalence of prescription resumption in our study is perhaps surprising, given that we know 
that the rate of prescription cessation remains greater than the rate of symptom decline (1,6-9). The 
implication is that there is a population of young people who could benefit from resuming medication, 
but have not done so.  Indeed, reports of structural barriers to prescribing in adults with ADHD mean 
that we cannot assume that all those who could benefit from resuming medication are able to do so 
(15, 24). Qualitative research has also illuminated the journeys and struggles of adults seeking to re-
enter services.  In the recent CATCh-uS ADHD study, participants with ADHD who re-entered 
services in their twenties discussed their difficulties in managing their early adult lives without 
services or support (34).  Often, consequences such as job loss or criminal justice contact represented 
the triggers for them to attempt to re-enter services, a process which was sometimes prompted and 
assisted by a family member or partner.  Both CATCh-uS and earlier work by Matheson et al. (35) 
highlighted the considerable persistence often required to seek and obtain support and treatment for 
ADHD as an adult. This suggests that many of the most vulnerable individuals with ongoing ADHD 
symptoms may not have the resources required to surmount the barriers to re-enter services.  
Our research therefore adds support to the case for designing and commissioning more flexible 
models of prescribing support in ADHD, with easier exit and entry points. Brinkman et al.’s survey of 
participants in the MTA trial reported that many adolescents recognized the need for medication only 
after stopping, and suggested that a ‘start-stop-start’ pattern with the attendant flexibility may be their 
preferred model (12).  Early findings from the CATCh-uS study also illustrate how adolescents have 
differing conceptualisations of what ADHD means to them and what it means for their future as 
adults, which influence how ‘ready’ they are for transition and whether they ‘drift’ away from 
services (34). Therefore, when and if adolescents stop their medication, acknowledging and 
discussing contingencies such as what to do if symptoms re-emerge or affect their adult life could be a 
helpful strategy.  
However, alongside a need for flexibility, our findings also paint a picture of greater complexity in 
those who resume prescriptions, contributing to the debate about where ADHD is best managed for 
adults with the condition.  As argued by Coghill, symptom monitoring, monitoring of impairment and 
functioning and monitoring of comorbid conditions are skilled and time consuming tasks which may 
be best suited to specialist care (24).  
Research implications  
NICE guidance, and consensus statements outline recommendations on prescribing in ADHD, but 
research suggests implementation and service provision is highly variable (14, 15, 30, 34). Very 
recent reports highlight concern that some UK Adult ADHD services may be in the process of being 
decommissioned, and others have expanding waits (36). Our findings, in line with other research, also 
suggest that some adult ADHD prescribing may be taking place without specialist supervision, raising 
questions about how well GPs are being supported to take on sole responsibility for this aspect of care 
(14, 30). Consequently, it is important to better understand the role of primary care, and the needs and 
perspectives of GPs; this is an area which has been little studied to date. 
There is also a need to develop and evaluate models of managing ADHD in transition and early 
adulthood which address the tensions between prescribing for a potentially complex patient group, 
and a more flexible approach to medication management.  In particular, findings from the MTA study 
and CATCh-uS suggest that the ‘stop-start’ pattern of medication is likely to be influenced by the 
patient’s current circumstances and context (12, 34); future studies could test and explore flexible 
prescribing models further, considering patient preference, professionals perspectives’ and tracking 
outcomes (37) . It would also be helpful for future research using primary care databases to examine 
patterns of resumption beyond the age range of this study into the mid-thirties and beyond, as this 
would provide a fuller picture of adults seeking to re-engage with services and treatment.  
Conclusion 
This study suggests that most of those who stop medication in adolescence do not have their 
prescriptions resumed in early adulthood. Those that could benefit from resuming their medication as 
adults need to be able to do so in a safe and stable manner in order to experience improved outcomes. 
Our findings raise questions around whether current models of care and prescribing are suitable and 
flexible enough for young adults with ADHD, and whether professionals in primary care are 
adequately supported by specialist services in managing this group. As a result, there is a need for 
studies to examine the barriers to implementation of guidance, and for evaluation to develop and 
refine feasible and acceptable models within an environment of resources constraints.  
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Table 1: Outcomes of young people who stopped ADHD prescriptions aged 14-18 
Outcome n Percentage 
Did not restart 1,331 92.4% 
Restarted age 20  66 4.6% 
Restarted age 21 19 1.3% 
Restarted age 22 15 1.0% 
Restarted age 23 6 0.4% 
Restarted age 24 2 0.1% 
Restarted age 25 1 0.1% 
Total 1,440   100% 
Table 2: Resumption status by age of stopping ADHD prescription 
Age at stopping prescription Number restarting 
prescription (%) 
Age 14 (N=113) 6 (5.3%) 
Age 15 (N=209) 5 (2.4%) 
Age 16  (N=427) 24 (5.6%) 
Age 17  (N=372) 32 (8.6%) 
Age 18  (N=319) 42 (13.2%) 
 
Table 3: Resumption of primary care prescriptions for ADHD medication by recorded characteristic 
Characteristic Number resuming medication (%) 
Prescription for non-ADHD psychotropic  
(N=395) 
52 (13.2%) 
Referral recorded to Adult Mental Health Services (N=142) 28 (19.7%) 








Autism Spectrum Disorder 
(N=112) 
13 (11.6%) 






All cases (N=1440) 109 (7.6%) 
Table 4: Unadjusted and Adjusted Cox regression model for resumption of prescription aged 20-22 
Variable Unadjusted  Adjusted 
Hazard Ratio  
(95% CI) 
p value Hazard Ratio  
(95% CI) 
p value 
Female gender 1.91 (1.09 to 3.32) 0.02 1.81 (1.04 to 3.26) 0.05 
Referral recorded to Adult 
Mental Health Services 
3.27 (2.01 to 5.31) <0.0001 2.18 (1.30 to 3.66) 0.003 
Learning disability 3.64 (1.98 to 6.70) <0.0001 2.43 (1.25 to 4.74) 0.009 
Conduct disorder 1.32 (0.61 to 2.86) 0.48   
Autism Spectrum Disorder 1.99 (1.09 to 3.67) 0.03 1.47 (0.76 to 2.83) 0.26 
Anxiety or depression 1.57 (0.83 to 2.96) 0.16   
Substance misuse 2.57 (1.04 to 6.33) 0.04 1.81 (0.72 to 4.56) 0.21 
Antidepressant prescription 
aged 19 and over 
2.08 (1.28 to 3.41) 0.004 1.08 (0.63 to 1.86) 0.77 
Antipsychotic prescription 
aged 19 and over 
6.93 (3.97 to 12.1) <0.0001 3.58 (1.86 to 6.88) <0.0001 
Anxiolytic/hypnotic 
prescription aged 19 and over 
3.20 (1.60 to 6.39) <0.001 1.83 (0.88 to 3.80) 0.10 
Age at stopping medication (17 
or 18 versus 14-16) 
 
2.25 (1.43 to 3.53) <0.0001 2.04 (1.28 to 3.24) 0.003 
Table 5: Comparison of Non-ADHD Psychotropic prescribing in individuals who did and did not 
resume ADHD prescriptions 




P value  
for Chi-squared 
test 
Any non-ADHD psychotropic prescription, 
n (%) 
343 (25.8%) 52 (47.7%) <0.0001 
Antidepressant prescription, n (%) 228 (17.1%) 36 (33.0%) <0.0001 
Antipsychotic prescription, n (%) 136 (10.2%)  22 (20.2%) 0.001 
Anxiolytic/hypnotic prescription, n (%) 69 (5.2%) 13 (11.9%) 0.003 
Multiple prescribing (more than one 
category of non-ADHD psychotropic), n (%) 
 
79 (5.9%) 16 (14.7%) <0.0001 
 
 
 
 
 
 
 
